SCHEMBL22904286

SCHEMBL22904286

O=C1Cc2cccc(CNc3ccccc3)c2C(=O)N1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 7/20 0.50
CASP3 P42574 1/20 0.44
CASP7 P55210 1/20 0.44
CASP9 P55211 1/20 0.44
CASP6 P55212 1/20 0.44
CASP8 Q14790 1/20 0.44
MAP3K14 Q99558 1/20 0.44
PARP1 P09874 1/20 0.40
AHR P35869 2/20 0.39
PDK2 Q15119 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
P2RX4 Q99571 1/20 0.38
HIF1A Q16665 2/20 0.37
MAOA P21397 2/20 0.36
MAOB P27338 2/20 0.36
NISCH Q9Y2I1 1/20 0.36
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22904145 0.78 TDP2 (0.54) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904362 0.76 TDP2 (0.58) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904354 0.76 TDP2 (0.58) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904526 0.75 TDP2 (0.54) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904287 0.75 TDP2 (0.50) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904296 0.75 TDP2 (0.50) TDP2CASP3CASP7CASP9CASP6
SCHEMBL28350617 0.72 CES1 (0.46) PARP1HIF1AMAOAMAOBNISCH
SCHEMBL19414642 0.72 MAOA (0.46) PARP1SMN1; SMN2L3MBTL1HIF1AMAOA
SCHEMBL22904178 0.67 TDP2 (0.64) TDP2CASP3CASP7CASP9CASP6
SCHEMBL20886849 0.67 TDP2 (0.64) TDP2CASP3CASP7CASP9CASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021011631-A1 FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-01-21 WO disclosed
US-20160331734-A1 SUBSTITUTED N-ARYL PYRIDINONES AUSPEX PHARMACEUTICALS, INC. 2016-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160331734-A1 SUBSTITUTED N-ARYL PYRIDINONES COL1A1, COL2A1, COLGALT1 TDP2 3657/4885CASP3 2951/4885CASP7 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.